News Report · Oncology

FDA Approves Datopotamab Deruxtecan for TNBC: 36% ORR in TROPION-Breast02 Trial

June 09, 2026

Confirmed Objective Response Rate

36%

Median Progression-Free Survival

10.8 months

Clinical Perspective

Datopotamab deruxtecan offers a new treatment option for patients with unresectable or metastatic TNBC, demonstrating promising efficacy in a challenging patient population.

Dr. Meera Pillai · Oncology

Datopotamab deruxtecan (Datroway) achieved a confirmed objective response rate of 36% versus investigator's choice of chemotherapy in patients with unresectable or metastatic triple-negative breast cancer (TNBC) in the TROPION-Breast02 trial (HR 0.57; 95% CI 0.47-0.69) ^[2].

Clinical Context

Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). This subtype accounts for approximately 15-20% of breast cancer cases and is associated with a poorer prognosis compared to other breast cancer types. Current treatment options for TNBC are limited, particularly for patients who have progressed on standard therapies. The TROPION-Breast02 trial evaluates the efficacy of datopotamab deruxtecan, a Trop-2-directed antibody-drug conjugate, in patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.

Key Findings

The TROPION-Breast02 trial showed datopotamab deruxtecan reduced the risk of disease progression by 43% compared to investigator's choice of chemotherapy (HR 0.57; 95% CI 0.47-0.69) ^[2].
The trial enrolled 644 patients with unresectable or metastatic TNBC who had not received prior chemotherapy for their advanced disease ^[2].
Event rates: 36% objective response rate (ORR) for datopotamab deruxtecan versus 30% for chemotherapy ^[2].
The primary endpoint was confirmed objective response rate (ORR) assessed by blinded independent central review (BICR) ^[2].
Secondary endpoint results included median progression-free survival (PFS) of 10.8 months for datopotamab deruxtecan versus 5.6 months for chemotherapy (HR 0.57; 95% CI 0.47-0.69) ^[2].
Datopotamab deruxtecan is administered at a dose of 6 mg/kg as an intravenous infusion every three weeks ^[2].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Stomatitis reported with datopotamab deruxtecan — monitor during treatment ^[2].
Nausea reported — exact frequency not available in public source summary ^[2].
Fatigue reported ^[2].
Decreased leukocytes reported ^[2].
Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception ^[2].
Complete adverse event profile available in the full prescribing information for datopotamab deruxtecan (Datroway) ^[2].

What This Means for Clinical Practice

Datopotamab deruxtecan is indicated for adult patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy. The trial results support its use with a confirmed ORR of 36%. What additional data will emerge regarding long-term outcomes and safety in diverse populations?

Study Design

The TROPION-Breast02 trial was a multicenter, open-label, randomized trial involving 644 patients with unresectable or metastatic TNBC who had not received prior chemotherapy for their advanced disease. The primary endpoint was confirmed objective response rate (ORR), assessed by blinded independent central review (BICR) based on RECIST v1.1 criteria. The trial randomized patients 1:1 to receive either datopotamab deruxtecan or investigator's choice of chemotherapy, which included paclitaxel, nab-paclitaxel, capecitabine, eribulin, or carboplatin. The study was funded by Daiichi Sankyo and AstraZeneca, and key limitations include the exclusion of patients with a history of interstitial lung disease or pneumonitis requiring treatment with steroids.

FAQ

What is datopotamab deruxtecan approved for?

Datopotamab deruxtecan (Datroway) is approved for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy as of May 22, 2026.

How does datopotamab deruxtecan work?

Datopotamab deruxtecan is a Trop-2-directed antibody-drug conjugate that delivers a cytotoxic agent directly to cancer cells expressing the Trop-2 antigen, leading to cell death.

What is the recommended dose of datopotamab deruxtecan?

The recommended dose of datopotamab deruxtecan is 6 mg/kg administered as an intravenous infusion once every three weeks. Clinicians should consult current prescribing information for full dosing guidance.

What are the most common side effects of datopotamab deruxtecan?

Common side effects include stomatitis, nausea, fatigue, and decreased leukocytes. Exact frequencies are not available in public source summaries.

References

FDA — FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer

FDA Approves Datopotamab Deruxtecan for TNBC: 36% ORR in TROPION-Breast02 Trial

FDA Approves Datopotamab Deruxtecan for TNBC: 36% ORR in TROPION-Breast02 Trial

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

FAQ

References

Get weekly drug updates for Oncology in your inbox.

Related Drug Updates

FDA Panel Votes Against Camizestrant for ESR1-Mutated Breast Cancer

FDA Approves Imlunestrant for ESR1-Mutated Breast Cancer: 5.5 Months PFS Improvement

FDA Advisory Panel Discusses Camizestrant for ESR1-Mutated Breast Cancer

Verified HCP Portal